Literature DB >> 23207293

Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.

Thomas Tawadros1, Florian Alonso, Patrice Jichlinski, Noel Clarke, Thierry Calandra, Jacques-Antoine Haefliger, Thierry Roger.   

Abstract

The acquisition of neuroendocrine (NE) characteristics by prostate cancer (PCa) cells is closely related to tumour progression and hormone resistance. The mechanisms by which NE cells influence PCa growth and progression are not fully understood. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine involved in oncogenic processes, and MIF serum levels correlate with aggressiveness of PCa. Here, we investigated the regulation and the functional consequences of MIF expression during NE transdifferentiation of PCa cells. NE differentiation (NED) of LNCaP cells, initiated either by increasing intracellular levels of cAMP or by culturing cells in an androgen-depleted medium, was associated with markedly increased MIF release. Yet, intracellular MIF protein and mRNA levels and MIF gene promoter activity decreased during NED of LNCaP cells, suggesting that NED favours MIF release despite decreasing MIF synthesis. Adenoviral-mediated forced MIF expression in NE-differentiated LNCaP cells increased cell proliferation without affecting the expression of NE markers. Addition of exogenous recombinant MIF to LNCaP and PC-3 cells stimulated the AKT and ERK1/2 signalling pathways, the expression of genes involved in PCa, as well as proliferation and resistance to paclitaxel and thapsigargin-induced apoptosis. Altogether, these data provide evidence that increased MIF release during NED in PCa may facilitate cancer progression or recurrence, especially following androgen deprivation. Thus, MIF could represent an attractive target for PCa therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23207293     DOI: 10.1530/ERC-12-0286

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  14 in total

1.  Neuroendocrine differentiation of prostate cancer.

Authors:  Zhen Li; Clark J Chen; Jason K Wang; Elaine Hsia; Wei Li; Jill Squires; Yin Sun; Jiaoti Huang
Journal:  Asian J Androl       Date:  2013-03-18       Impact factor: 3.285

2.  Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.

Authors:  Olivia Twu; Daniele Dessí; Anh Vu; Frances Mercer; Grant C Stevens; Natalia de Miguel; Paola Rappelli; Anna Rita Cocco; Robert T Clubb; Pier Luigi Fiori; Patricia J Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

3.  Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.

Authors:  Qiang Dang; Lei Li; Hongjun Xie; Dalin He; Jiaqi Chen; Wenbing Song; Luke S Chang; Hong-Chiang Chang; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Oncol       Date:  2015-03-05       Impact factor: 6.603

4.  Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis.

Authors:  Shilpa Choudhary; Poornima Hegde; James R Pruitt; Thais M Sielecki; Dharamainder Choudhary; Kristen Scarpato; David J Degraff; Carol C Pilbeam; John A Taylor
Journal:  Carcinogenesis       Date:  2013-07-03       Impact factor: 4.944

Review 5.  Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  Front Oncol       Date:  2015-02-02       Impact factor: 6.244

6.  Impact of the microbial derived short chain fatty acid propionate on host susceptibility to bacterial and fungal infections in vivo.

Authors:  Eleonora Ciarlo; Tytti Heinonen; Jacobus Herderschee; Craig Fenwick; Matteo Mombelli; Didier Le Roy; Thierry Roger
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

Review 7.  Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.

Authors:  Alessandro Sciarra; Alessandro Gentilucci; Stefano Salciccia; Federico Pierella; Flavio Del Bianco; Vincenzo Gentile; Ida Silvestri; Susanna Cattarino
Journal:  J Inflamm (Lond)       Date:  2016-11-25       Impact factor: 4.981

8.  Sirtuin 5 Deficiency Does Not Compromise Innate Immune Responses to Bacterial Infections.

Authors:  Tytti Heinonen; Eleonora Ciarlo; Charlotte Théroude; Aimilia Pelekanou; Jacobus Herderschee; Didier Le Roy; Thierry Roger
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

9.  Influence of a six month endurance exercise program on the immune function of prostate cancer patients undergoing Antiandrogen- or Chemotherapy: design and rationale of the ProImmun study.

Authors:  Philipp Zimmer; Elke Jäger; Wilhelm Bloch; Eva Maria Zopf; Freerk T Baumann
Journal:  BMC Cancer       Date:  2013-06-03       Impact factor: 4.430

10.  Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.

Authors:  Vincenza Conteduca; Emanuela Scarpi; Samanta Salvi; Valentina Casadio; Cristian Lolli; Giorgia Gurioli; Giuseppe Schepisi; Daniel Wetterskog; Alberto Farolfi; Cecilia Menna; Delia De Lisi; Salvatore Luca Burgio; Himisha Beltran; Gerhardt Attard; Ugo De Giorgi
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.